18:38 , Feb 15, 2019 |  BC Week In Review  |  Financial News

Anchiano prices $30.5M NASDAQ offering

Anchiano Therapeutics Ltd. (Tel Aviv:ANCN; NASDAQ:ANCN) raised $30.5 million via a listing of ADSs on NASDAQ. On Feb. 12, the gene therapy company priced 2.6 million ADSs at $11.50, giving it a valuation of $78.5...
18:28 , Feb 12, 2019 |  BC Extra  |  Financial News

Anchiano slips after NASDAQ offering

Anchiano Therapeutics Ltd. (Tel Aviv:ANCN; NASDAQ:ANCN) slipped $0.70 to $10.80 on NASDAQ on Tuesday after raising $30.5 million in a listing of ADSs. The gene therapy company priced 2.6 million ADSs at $11.50, giving it...
22:49 , Jan 5, 2018 |  BC Week In Review  |  Company News

BioCanCell shareholders turn down offer to go private

BioCanCell Therapeutics Inc. (Tel Aviv:BICL) said its shareholders did not approve a full tender offer led by its largest shareholder Clal Biotechnology Industries Ltd. (Tel Aviv:CBI) to take BioCanCell private. According to BioCanCell, the offering...
22:20 , Nov 20, 2017 |  BC Extra  |  Company News

Management tracks: Shire, Aveo

Shire plc (LSE:SHP; NASDAQ:SHPG) named Thomas Dittrich CFO, effective early 2018. He is CFO at machinery manufacturing firm Sulzer Ltd. (SIX:SUN). In August, Shire said Jeff Poulton will depart as CFO at year end (see...
01:31 , Sep 2, 2017 |  BioCentury  |  Strategy

Back to School: Breach of contract

Merck & Co. Inc. Chairman and CEO Kenneth Frazier’s resignation in August from a White House advisory council was an act of principle, and a reminder that 30 years ago Merck was one of the...
22:27 , Mar 16, 2017 |  BC Innovations  |  Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Financial News

Noxxon completes private placement

Noxxon Pharma N.V. (Euronext:ALNOX), Berlin, Germany   Business: Cancer   Date completed: 2016-09-23   Type: Private placement   Raised: EUR2.8 million ($3.2 million)   Shares: 132,079   Shares after offering: 2.1 million   Investors: NGN...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Lighting up neoantigens

Investors led by Third Rock Ventures put $55 million into Neon Therapeutics Inc. to exploit recently discovered neoantigen biology from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute . Neon will develop...
00:58 , Oct 2, 2015 |  BC Extra  |  Financial News

Investors light up Neon with $55M series A

Immuno-oncology newco Neon Therapeutics Inc. raised $55 million in a series A round led by new investor Third Rock Ventures. Other new investors included Clal Biotechnology Industries Ltd. (Tel Aviv:CBI) and Access Industries. Neon is...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

DiaPep277: Phase III data

Horizon Pharma plc (NASDAQ:HZNP, Dublin, Ireland) said that Clal Biotechnology Industries Ltd. (Tel Aviv:CBI, Tel Aviv, Israel) provided the Tel Aviv Stock Exchange notice of data from the double-blind, international Phase III DIA-AID 2 trial...